Dana Rath,
President, CEO & CFO

Craig Bell,

Dr. Jack Gauldie,

Pierre V. LaTraverse,

Barry Markowsky,

David F. Masotti,

Dr. Eleanor Fish,
Senior Technical Advisor




Dana Rath - President, CEO, CFO, & Director

Mr. Rath is a senior financial executive and entrepreneur with extensive experience in biotech and computer software industries. Mr. Rath has over 30 years of experience in advising private and public companies on corporate and legal matters relating to finance, accounting, treasury and taxation and as both a chartered accountant and an attorney brings a well-rounded perspective to management. He is a CPA, CA and holds degrees from McGill University (B.Sc.) and University of Ottawa (LL.B) and is currently the President, CEO & CFO of Defyrus. Mr. Rath has also held positions as the CFO of Defyrus, Iscopia Software, as the Vice-President Finance & Administration of Nexia Biotechnologies and as a tax specialist at both Abbott Laboratories Canada and Ernst & Young.


Craig Bell - Director

Mr. Craig Bell serves as the Chief Operating Officer, Executive Vice President Assets and Portfolio Manager at PIC Investment Group Inc. Mr. Bell has an extensive background in business management, people management, marketing, sales and business analysis. Prior to joining PIC Group of Companies in 2008, he worked with a number of Fortune 100 companies.


Dr. Jack Gauldie - Director

Dr. Jack Gauldie received his B.Sc. from McMaster University and Ph.D. from University College, London, England, and was recently awarded a DSc from McMaster University. Since 1970 has been at McMaster University, Faculty of Health Sciences in the Department of Pathology and Molecular Medicine. He is Distinguished University Professor and was Chairman of the Department of Pathology and Molecular Medicine for fifteen years, where he also established the Fitzhenry Vector Facility, a cGMP level facility providing small clinical lots of viral vectors for human vaccine trials. He has published over 400 scientific papers and consults widely in the pharmaceutical industry on aspects of inflammation, immunity and vaccine development. Dr. Gauldie was a member of the Advisory Board of the Institute for Infection and Immunity of CIHR and a member of the Research Management Committee of CANVAC, the Canadian Network for Vaccines and Immunotherapeutics. He serves on the scientific advisory board of several companies, is on the editorial board of a number of basic and clinical journals, and is a regular reviewer of grants from Canadian, UK and US agencies. He is Chair of the Advisory Board of the Ontario Research Fund and Acting Chair of the Board of Genome Ontario and a member of the Canadian Foundation for Innovation. He was Co-Chair of the Medical Review Panel and a member of the Medical Advisory Board for the CIHR Canada Gairdner International Awards. Dr. Gauldie is a Fellow of the Royal Society of Canada (FRCS) and was recently appointed a member of the Order of Canada (CM).


Pierre V. LaTraverse - Director

Mr. Pierre V. LaTraverse is a practising lawyer with over 30 years of experience in civil and commercial litigation. He has been a member of the Bar of Québec since 1985 and of the New York State Bar since 1991. He holds both a Bachelor of Civil Law (B.C.L. 1983) and a Bachelor of Laws (LL.B.-1984) from McGill University. As lead counsel, Mr. LaTraverse has represented both plaintiffs and defendants before all court levels, as well as in private arbitration and mediation. He has also worked closely with lawyers, experts and foreign legal advisors in multi-jurisdictional litigation. Since 2000, Mr. LaTraverse has been practicing as an independent lawyer at LaTraverse Avocats Inc., a boutique law firm, member of the INBLF (The International Network of Boutique Law Firms) of which he is currently the President of the Montreal chapter. http://www.latraverse.ca/


Barry Markowsky - Director

Mr. Markowsky is a senior pharmaceutical executive who brings considerable business development experience as the former general manager of ViiV Healthcare, as Vice-President, Business Development at Glaxo Wellcome, Inc. and from senior executive positions at Shering-Plough, Miles Laboratories and Ayerst Laboratories. He has more than 16 years of Board Member experience. Barry earned an MBA from the University of Toronto as well as a Master of Science in Bacteriology & Virology, and Bachelor of Science (Honours).


David F. Masotti - Director

Mr. Masotti is a senior executive, corporate director and entrepreneur with extensive experience in a range of industries including telecommunications, aerospace, bio-defense and venture capital. Mr. Masotti brings considerable operational experience as the former President of Spar Aerospace Systems, Rogers Telecommunications, and Chemtrade Logistics Income Fund and venture capital experience as a Managing Director of Tancho Innovation Capital. Masotti serves as a Director at Firan Technology Group (TSX:FTG) and Deveron UAS Corp. (CSE:DVR). Previously Mr. Masotti served on the Board of Trustees for Queen’s University, the Board of COM DEV (TSX:CDV) and several other private and public companies. He earned an MBA from the Harvard Business School and a B.Sc. in Electrical Engineering from Queen’s University and was a recipient of the Top 40 under 40 business award.


Scientific Advisors


Dr. Eleanor Fish - Senior Technical Advisor

Dr. Fish is recognized international expert in the field of cytokines with a focus on interferons in particular, and she holds the position of Senior Scientist at the Toronto General Hospital Research Institute. Dr. Fish is a Professor in the Department of Immunology at the University of Toronto, and is the Tier 1 Canada Research Chair in Women’s Health and Immunobiology. Dr. Fish received her M.Phil. from King’s College, London, U.K. and her Ph.D. in Immunology and Cell Biology from the University of Toronto.